Platelet Function Tests

• 

  Subject Areas on Research

  • "Blueprinting" thrombogenicity and antithrombotic drug response at the bedside in patients presenting emergently with symptoms of acute stroke. 
  • A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes. 
  • A diagnosis of heparin-induced thrombocytopenia with combined clinical and laboratory methods in cardiothoracic surgical intensive care unit patients. 
  • A new method of representing drug-induced platelet inhibition: better description of time course, response variability, non-response, and heightened activity. 
  • ABO blood group and bleeding after coronary artery bypass graft surgery. 
  • ANTARCTIC: platelet function testing to adjust therapy. 
  • Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. 
  • Acceptance of high platelet reactivity as a risk factor: now, what do we do about it? 
  • Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. 
  • An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. 
  • Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention. 
  • Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. 
  • Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. 
  • Antiplatelet therapy and platelet function testing. Introduction. 
  • Antiplatelet therapy in pediatric cardiovascular patients. 
  • Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events. 
  • Assessing the current role of platelet function testing. 
  • Assessment of oral antithrombotic therapy by platelet function testing. 
  • Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center. 
  • Association of measured platelet reactivity with changes in P2Y12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study. 
  • Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. 
  • Clinical utility of available methods for determining platelet function. 
  • Clinical utility of the platelet function analyzer (PFA-100) for the assessment of the platelet status in patients with congestive heart failure (EPCOT trial). 
  • Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding. 
  • Cluster-randomized clinical trial examining the impact of platelet function testing on practice: the treatment with adenosine diphosphate receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome prospective open label antiplatelet therapy study. 
  • Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. 
  • Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. 
  • Contemporary use of platelet function and pharmacogenomic testing among patients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States. 
  • Current evidence and clinical implications of aspirin resistance. 
  • Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. 
  • Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. 
  • Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials. 
  • Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. 
  • Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy? 
  • Does heart failure etiology, New York Heart Association class, or ejection fraction affect the ability of clopidogrel to inhibit heightened platelet activity? 
  • Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. 
  • Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial. 
  • Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. 
  • Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl). 
  • Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity. The result of the ACCEL-DIP Study. 
  • Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy). 
  • Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation, Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study. 
  • Enhancing standard cardiac rehabilitation with stress management training: background, methods, and design for the enhanced study. 
  • Ether lipid metabolism by AADACL1 regulates platelet function and thrombosis. 
  • Evaluating the clinical usefulness of platelet function testing: considerations for the proper application and interpretation of performance measures. 
  • Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. 
  • Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study. 
  • Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT trial. With special reference to the Hemodyne hemostatic analyzer. Whole Blood Impedance Aggregometry for the Assessment of Platelet Function in Patients with Congestive Heart Failure. 
  • First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. 
  • First report of the point-of-care TEG: A technical validation study of the TEG-6S system. 
  • High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases. 
  • High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low? 
  • Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation. 
  • Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. 
  • Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel. 
  • Impact of anemia on platelet response to clopidogrel in patients undergoing percutaneous coronary stenting. 
  • Inflammation and circulating endothelial progenitor cells in patients with coronary artery disease and residual platelet reactivity. 
  • Influence of CYP2C19*2 and *3 loss-of-function alleles on the pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention: the results of the ACCEL-DOUBLE-2N3 study. 
  • Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention. Results of the ACCEL-BLEED study. 
  • Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients. 
  • Initial platelet activity may predict efficacy after chronic oral glycoprotein IIb/IIIa blockade: should we still consider uniform treatment regimens? 
  • Investigating the mechanisms of hyporesponse to antiplatelet approaches. 
  • Is There a Role for Preoperative Platelet Function Testing in Patients Undergoing Cardiac Surgery During Antiplatelet Therapy? 
  • Is light transmittance aggregometry still a useful tool to assess pharmacodynamic effects of antiplatelet therapy? 
  • Managing clotting: a North American perspective. 
  • Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. 
  • Oxylipid Profile of Low-Dose Aspirin Exposure: A Pharmacometabolomics Study. 
  • Peri-operative platelet function testing: the potential for reducing ischaemic and bleeding risks. 
  • Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial. 
  • Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. 
  • Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration: the ACCEL-PARAZOL study. 
  • Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2). 
  • Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. 
  • Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. 
  • Platelet Function Testing in Patients on Antiplatelet Therapy before Cardiac Surgery. 
  • Platelet RNA as a novel biomarker for the response to antiplatelet therapy. 
  • Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study. 
  • Platelet activity associated with concomitant use of clopidogrel and proton pump inhibitors in children with cardiovascular disease. 
  • Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. 
  • Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients. 
  • Platelet function measurement in elective percutaneous coronary intervention patients: exploring the concept of a P2Y₁₂ inhibitor therapeutic window. 
  • Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. 
  • Platelet function monitoring in patients with coronary artery disease. 
  • Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. 
  • Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis. 
  • Point-of-care platelet function analysis ready for prime time? 
  • Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population. 
  • Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry. 
  • Progress in point-of-care laboratory testing for assessing platelet function. 
  • Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading. 
  • Relation of High Lipoprotein (a) Concentrations to Platelet Reactivity in Individuals with and Without Coronary Artery Disease. 
  • Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. 
  • Response variability and the role of platelet function testing. 
  • Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. 
  • Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. 
  • Sonorheometry assessment of platelet function in cardiopulmonary bypass patients: Correlation of blood clot stiffness with platelet integrin αIIbβ3 activity, aspirin usage, and transfusion risk. 
  • The difference between clopidogrel responsiveness and posttreatment platelet reactivity. 
  • The effect of aspirin on endothelial progenitor cell biology: preliminary investigation of novel properties. 
  • The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. 
  • The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting. 
  • The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. 
  • The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patient. 
  • Thromboembolism after WATCHMANTM in a clopidogrel non-responder: A case for concern? 
  • Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation. 
  • Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy. 
  • Use of a new platelet function analyzer to detect von Willebrand disease in women with menorrhagia. 
  • Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data. 
  • Viral respiratory tract infections increase platelet reactivity and activation: an explanation for the higher rates of myocardial infarction and stroke during viral illness. 
  • Whole blood impedance aggregometry for the assessment of platelet function in patients with congestive heart failure (EPCOT Trial). 
  • von Willebrand disease in the 21st century: current approaches and new challenges. 
• 

  Keywords of People

  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology